Abbott Reports the Initiation of TRANSCEND Trial Assessing Deep Brain Stimulation System to Manage Severe Depression (TRD)
Shots:
- Abbott has begun the pivotal TRANSCEND trial of deep brain stimulation (DBS) system for managing TRD. The system was designated as breakthrough device by the US FDA
- The trial will assess DBS system in TRD subjects (n=100; 22-70yrs.), failed on at least 4 antidepressant therapies, with the device activated in the treatment arm (not in control group). All devices will be activated post 1yr., & participants will be followed for 2yrs. more to find improvement in MADRS
- Leads of the system are placed in a brain region linked to depression & connected to a stimulator (placed in chest), sending electrical pulses to reduce depression. Prior studies showed 50% sustained symptoms improvement in 3/4 patients over 2-8yrs.
Ref: Abbott | Image: Abbott
Related News: Abbott’s Deep Brain Stimulation System Receives the US FDA's Breakthrough Device Designation for Severe Depression
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
